Introduction: Ovarian cancer is the leading cause of death from gynecologic cancers, in
fact,> 80% of cases are diagnosed as advanced-stage disease associated with a high …

In patients with advanced ovarian carcinomas, the first-line treatment has historically relied
on debulking surgery and platinum-based chemotherapy. If the major therapeutic/prognostic …

Epithelial ovarian cancer (EOC) is the 6th most common cancer among women in the UK
(2014) and accounts for 4% of all new cases of cancer in females: it has the highest mortality …

This manuscript reports the consensus statements regarding the design and conduct of
clinical trials in patients with newly diagnosed and recurrent epithelial ovarian cancer (EOC) …

Objectives To measure HE4 levels in urine from normal donors, patients with LMP tumors
and ovarian cancer patients and to correlate levels with clinical factors in ovarian cancer …

Background To evaluate the diagnostic value of adding human epididymis protein 4 (HE4),
cancer antigen 125 (CA125) and risk of malignancy algorithm (ROMA) to ultrasound for …

Available evidence on the proliferation-promoting effect of HE4 remains controversial, and
few studies have been carried out on the molecular mechanism of chemoresistance …

Background This study assessed the prognostic value of HE4 marker measurements at
various stages of first-line chemotherapy for ovarian cancer. Methods The study consisted of …

Introduction: Ovarian cancer (OC) is one of the leading causes of cancer-related death in
women. Accumulating evidence showed an evolving role of HE4 in monitoring the …

Background The addition of human epididymis protein 4 (HE4) to carbohydrate antigen 125
(CA125) in ovarian cancer (OC) assessment has been proposed. We compared the clinical …